Advanced ADCs And Expanding Emerging Markets Will Redefine Oncology Treatment
AN
AnalystHighTarget
Not Invested
Consensus Narrative from 17 Analysts
Published
13 Jul 25
Updated
15 Aug 25
AnalystHighTarget's Fair Value
JP¥6,800.00
41.7% undervalued intrinsic discount15 Aug
JP¥3,963.00
1Y
-32.4%7D
11.1%